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Retrospective Analysis of Structural 
Disease Progression in Retinitis 
Pigmentosa Utilizing Multimodal 
Imaging
Thiago Cabral1,2,3,4, Jesse D. Sengillo1,2,5, Jimmy K. Duong6, Sally Justus1,2, Katherine 
Boudreault1,2,7, Kaspar Schuerch2, Rubens Belfort Jr4, Vinit B. Mahajan8, Janet R. Sparrow2,9 & 
Stephen H. Tsang1,2,9
In this report, we assess the natural progression rate of retinitis pigmentosa (RP) over an 
average of three years using spectral-domain optical coherence tomography (SD-OCT) and short 
wavelength fundus autofluorescence (SW-AF). Measurement of the ellipsoid zone (EZ) line width 
and hyperautofluorescent ring diameters was performed in 81 patients with RP in a retrospective, 
longitudinal fashion. Rate of structural disease progression, symmetry between eyes, and test-
retest variability were quantified. We observed on average, EZ-line widths decreased by 140 µm 
(5.2%, p < 0.001) per year, and average horizontal and vertical hyperautofluorescent ring diameters 
decreased by 149 µm (3.6%, p < 0.001) and 120 µm (3.9%, p < 0.001) per year, respectively. The 95th 
percentile of this cohort had differences in progression slopes between eyes that were less than 154 µm, 
118 µm, and 132 µm for EZ-line width and horizontal and vertical ring diameters, respectively. For all 
measures except horizontal ring diameter, progression rates were significantly slower at end-stage 
disease. From our data, we observed a statistically significant progression rate in EZ line width and 
SW-AF ring diameters over time, verifying the utility of these measurements for disease monitoring 
purposes. Additionally, calculated differences in progression slopes between eyes may prove useful for 
investigators evaluating the efficacy of unilateral treatments for RP in clinical trials.
Retinitis pigmentosa (RP) is an inherited retinal disorder that causes progressive photoreceptor death and sub-
sequent irreversible vision loss. Affecting approximately 1 in 4000 individuals worldwide, RP patients typically 
present with night blindness followed by a constricting visual field and eventually, visual impairment or severe 
blindness1, 2. Mutations in more than sixty-seven genes have been identified to cause non-syndromic RP and3–5, 
despite this genetic heterogeneity, a similar end-result of photoreceptor cell dysfunction and cell death results6. 
Specialized genetic counseling and optimizing residual vision remain central to the management of RP, as there 
is currently no treatment that reverses disease progression7. However, numerous gene-, drug-, and cell-based 
therapy clinical trials are underway for inherited retinal degenerations including RP, highlighting the need for 
studies defining natural disease history. A previous study from our group by Sujirakul et al.8 observed ellipsoid 
zone (EZ)-line width and hyperautofluorescent ring diameters to be a reliable measure for RP progression. In a 
large cohort over a mean follow-up of two years, the investigators quantified disease progression rate and assessed 
for influence of other factors. Continued long-term tracking of RP disease progression yields important data that 
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can serve as a metric for future clinical trials and patient counseling, and thus the present analysis is a follow-up 
to the previous study over a longer follow-up period.
Traditionally, tests of visual or retinal function were first employed to track disease progression, such as visual 
acuity, visual fields, and electroretinography9. Visual acuity decreases slowly with age in comparison to visual 
field, in which concentric visual field loss is more progressive and typically will spare a portion of the patient’s 
central vision. Mid-peripheral scotomas are also observed in many patients, likely because this area of the fundus 
contains the highest rod density9, 10. Although these tests correlate to the perceptual experience of the patient, 
intersessional visual acuity and field measurements are variable. Such measurements for RP patients require 
larger changes to confidently identify progression and benefit from a single experienced operator administering 
the test; this is likely due to the high subjectivity and low test-retest reliability of these metrics11–13. Furthermore, 
variability of visual acuity and field increases with disease severity in RP, which is pertinent to RP clinical trials, as 
most enrolled patients have advanced-stage disease14.
Objective visual function is attained using the electroretinogram (ERG) and is more sensitive. Inherited 
retinal disease can manifest on ERG at an early-stage of disease prior to any structural change and provides a 
prognosis for future visual function15. Physicians alter the adaptation state and light stimulus to yield different 
information from the ERG. Although this modality has been useful in monitoring disease progression and treat-
ment response16, its intrinsic variability between sessions and large threshold for significant change limit its use 
over short intervals17–21. As such, we decided to take advantage of two non-invasive imaging modalities. High 
resolution SD-OCT visualizes the ellipsoid zone of the retina, an area that approximates the perceptual experience 
of a patient, as it correlates to visual field boundaries and can be used to monitor progression22–27 (Fig. 1). Short 
wavelength fundus autofluorescence (SW-AF) imaging of the retina is another technique used to assess inherited 
retinal disease and takes advantage of a major fluorophore, lipofuscin, that increasingly accumulates in the retinal 
pigment epithelium in diseased states28. It was previously observed that some RP patients possess a progressively 
constricting hyperautofluorescent ring on SW-AF, which correlates with worsening of visual function over time 
as measured by pattern ERG29. Subsequent analyses have confirmed this relationship to visual function and struc-
tural changes, such as abnormalities of the EZ on SD-OCT28, 30–42. Here, we provide progression rates for RP over 
a three-year average follow-up utilizing SD-OCT and SW-AF imaging.
Results
Clinical data. Eighty-one patients were followed for an average of 3.1 years (SD 1.7 years; median of 3 years 
with an interquartile range of 1.8, 4.6), defined by the amount of time between the first and last visit in which the 
right eye was imaged with SD-OCT imaging, as this imaging modality was utilized more frequently compared 
Figure 1. Longitudinal SD-OCT and SW-AF images of a 16-year-old man with autosomal dominant retinitis 
pigmentosa associated with a mutation in the PRPF31 gene. SW-AF images (left column) show characteristic 
hyperautofluorescent rings and SD-OCT (right column) images visualize the EZ line. Solid lines; sample 
measurement. Dashed lines; initial measurement. Asterisk; endpoints on EZ-line.
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to SW-AF. In our cohort, 44 (54%) patients were male and 37 (46%) were female. Of these patients, 24 (30%) 
were diagnosed with autosomal dominant RP (ADRP), 53 (65%) were diagnosed with autosomal recessive RP 
(ARRP), and 4 (5%) were diagnosed with X-linked RP (XLRP). Twelve patients (15%) had a history of bilat-
eral hearing loss consistent with Usher Syndrome. The average age of patients at first visit was 39 ± 19 years old 
(mean ± SD). Clinical and genetic data is summarized in Table 1 and distribution of follow-up time is shown 
in Table 2. Regarding imaging of the EZ-line, 78 of the patients (96%) had at least one eye with an EZ within 
the SD-OCT field of view. The 3 patients with EZs that extended outside the SD-OCT field of view each had a 
measurable hyperautofluorescent ring. Different SW-AF patterns were found as expected. Eleven of the patients 
(13.6%) included in this study were observed to have cystoid macular edema (CME).
Rate of progression. EZ-line width and hyperautofluorescent ring diameters are presented graphically as 
a function of time (Fig. 2). Linear mixed models with random intercepts and slopes were used to estimate pro-
gression rate in this study. Progression rate analysis for the right and left eyes are shown in Tables 3 and SI, 
respectively. The estimated average shortening of EZ-line width amongst right eyes was 140 ± 12 μm per year 
(mean ± SE, p < 0.001), representing approximately 0.5 degrees of visual field per year. Similarly, the estimated 
mean constriction of horizontal and vertical diameter was 149 ± 15 μm and 120 ± 14 μm per year (p < 0.001), 
respectively. Similar rates were observed in left eyes (Table SI). Progression rates were slower for patients with 
EZ-lines and ring diameters that were ≤ 3000 μm in size at baseline, with EZ-line width, horizontal diameter, and 
vertical diameter shortening at an average rate of 113 ± 14 μm, 109 ± 27 μm, 86 ± 14 μm per year in the right eye, 
respectively. For baseline measurements > 3000 μm, progression rates were faster, with EZ-line width, horizontal 
diameter, and vertical diameter shortening at an average rate of 200 ± 20 μm, 170 ± 17 μm, 169 ± 19 μm per year 
in the right eye, respectively (Table 3). Again, similar results were observed in left eyes (Table S1).
Reliability of measurements. To assess whether the three measurements were reliable, they were ana-
lyzed using descriptive statistics (Table 4) and intraclass correlation. Of note, the 95th percentile of the differ-
ence between test and retest was less than 74 μm for EZ-line width, 77 μm for horizontal diameter, and 67 μm 
for vertical diameter. High intraclass correlation of each measurement was observed, indicating high reliability, 
specifically 0.9998 for EZ-line width, 0.9998 for horizontal diameter, and 0.9998 for vertical diameter. The three 
measurements are strongly correlated to each other during the first patient visit (Fig. 3): r = 0.97 between EZ-line 
width and horizontal diameter, r = 0.95 for EZ-line width and vertical diameter, and r = 0.98 for horizontal diam-
eter and vertical diameter.
Symmetry of disease progression between eyes. Descriptive statistics was used to compare progres-
sion rates between eyes of the patient (Table 5). The absolute difference between slopes of progression in each eye 
of every patient was calculated. Of note, the 95th percentile of the differences in slope of progression between each 
eye were 154 μm, 118 μm, and 132 μm for EZ-line width, horizontal diameter, and vertical diameter respectively.
Examining for possible interactions. The effects of age, gender, mode of inheritance, and initial baseline 
measurement on progression rate were all evaluated by fitting linear mixed models of disease progression with 
time, these factors, and interactions of these factors with time (Tables SII–SV). Examining the estimate for the 
interaction term allows us to investigate whether progression varies by another factor. Age, gender, and mode of 
inheritance did not significantly affect progression rate in our patient cohort, similar to our previous investigation 
(Tables SII, SIII, SIV, respectively). Disease progression rate was observed to be a function of initial baseline meas-
urement. We examined this in two ways, dichotomizing baseline values at 3000 µm (Table 3 and SV) and keeping 
baseline as a continuous value (Table SVI). For patients with baseline measurements >3000 μm, the average pro-
gression rate of the right and left eye was calculated to be significantly faster for ellipsoid zone line width and ver-
tical ring diameter. Similar results were observed for the left eye (Tables SI and SV). For horizontal ring diameter, 
the p-value for the interaction terms were 0.06 and 0.32 for right eye and left eye respectively. (Table 3 and SV). 
When using continuous baseline values, results for ellipsoid zone line width and vertical ring diameter were 
Inheritance Subjects Proportion Genes Implicated (# of Patients)
ARRP 41 50.6% USH2A (2), PDE6B (2), PDE6A (2), CNGB1 (2), MERTK (2), MAK1 (1), NPHP1 (1), EYS (1), CRB1 (1), RGR (1), Unknown (26)
ADRP 24 29.6% RHO (4), PRPF31 (3), RP1 (3), Unknown (14)
Usher Syndrome 12 14.8% USH2A (5), GPR98 (1), PCDH15 (1), Unknown (5)
XLRP 4 5% RPGR (3), Unknown (1)
Table 1. Summary of clinical and genetic characteristics of the cohort. ARRP autosomal recessive retinitis 
pigmentosa, ADRP autosomal dominant retinitis pigmentosa, XLRP X-linked retinitis pigmentosa.
n
Mean 
(yrs)
Standard 
Deviation
Quantiles
Minimum 25th Median 75th Maximum
77 3.1 1.7 0.00 1.8 3.0 4.6 6.1
Table 2. Distribution of follow-up time as defined by ellipsoid zone measurements in the right eye.
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similar, i.e., the interactions were also significant. For horizontal ring diameter, the p-values for the interaction 
terms were 0.002 and 0.13 for right eye and left eye respectively.
Discussion
Overall, this study observed that EZ-line width measured by SD-OCT and hyperautofluorescent ring diameters 
measured with fundus SW-AF can detect progression in RP patients over a mean follow-up of 3 years, with each 
measurement highly correlated to the other; this parallels results of a two-year follow-up study performed by 
our group8. Progression rates were assessed using linear mixed models and comparable between the two stud-
ies. Although RP is thought to exhibit an exponential decay in degeneration, linear modeling is appropriate for 
approximating short intervals such as three years8. The mean annual decrease from average baseline EZ-line 
width was 5.2% per year, and 3.6% and 3.9% per year for horizontal and vertical hyperautofluorescent ring diam-
eter; this is consistent with our previous report of 4.9%, 4.1%, and 4.0% per year, respectively. Although different 
statistical methods have been employed in a variety of published studies monitoring annual changes in functional 
Figure 2. Trajectory of progression. Graphical representation of structural progression of each RP patient 
for EZ line width (first row), horizontal ring diameter (second row), and vertical diameter (third row). The 
raw data for each individual patient, followed time at each visit, is represented in the first column. Overall 
progression (second column), progression for patients with a baseline measurement ≤3000 µm (third column), 
and progression for patients with a baseline measurement >3000 µm (fourth column) is illustrated as a linear 
approximation for each patient. Single bold line in each graph represents average progression.
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and structural loss in RP patients, our results approximate previous findings24, 25, 37, 44. Given these data, EZ-line 
width and hyperautofluorescent ring diameters may serve as longitudinal outcome measures in clinical trials. 
Our study provides an estimated annual disease progression, which is useful for patient counseling and assessing 
efficacy of new treatments.
Despite that functional tests may appear subsidiary for tracking disease progression compared to objective 
structural measurements, they remain important. Representing a patient’s functional experience through sub-
jective testing such as best-corrected visual acuity and visual fields provides useful information to clinicians. 
Large changes in visual function determined under consistent testing environments may prove significant as an 
Outcome
Progression ± SE 
(µm/year)
Progression 
(degrees/year) P Value
Ellipsoid zone overall 140 ± 12 0.49 <0.001
 Baseline ≤ 3000 µm 113 ± 14 0.40 <0.001
 Baseline > 3000 µm 200 ± 20 0.70 <0.001
Horizontal diameter overall 149 ± 15 0.52 <0.001
 Baseline ≤ 3000 µm 109 ± 27 0.38 <0.001
 Baseline > 3000 µm 170 ± 17 0.60 <0.001
Vertical diameter overall 120 ± 14 0.42 <0.001
 Baseline ≤ 3000 µm 86 ± 14 0.30 <0.001
 Baseline > 3000 µm 169 ± 19 0.60 <0.001
Table 3. Rate of progression in the right eye of advanced-stage retinitis pigmentosa calculated using spectral-
domain optical coherence tomography and fundus autofluorescence. SE standard error.
Number of 
images Mean ± SD
Lower 
Quartile Median
Upper 
Quartile
95th 
Percentile
Ellipsoid zone width 539 17 ± 28 4 7 17 74
Horizontal diameter 336 20 ± 37 3 8 19 77
Vertical diameter 340 18 ± 27 4 8 20 67
Table 4. Descriptive statistics of the absolute difference between test and retest measurements for structural 
imaging parameters used to monitor retinitis pigmentosa progression. All units are µm. SD standard deviation.
Figure 3. Correlation between measurements for initial visit. Each of the three structural measurements were 
plotted as a function of the other two measurements. Scatterplots show high correlation between EZ-line width 
and both SW-AF ring diameters (first and second panel), and between horizontal and vertical ring diameters 
(third panel).
Number of 
patients Mean ± SD
Lower 
Quartile Median
Upper 
Quartile
95th 
Percentile
Ellipsoid zone width 73 54 ± 47 19 39 78 154
Horizontal diameter 47 50 ± 48 11 36 74 118
Vertical diameter 47 37 ± 47 8 21 41 132
Table 5. Descriptive statistics of the absolute difference between slopes of rate of progression between eyes 
measured with structural imaging parameters in retinitis pigmentosa. All units are µm. SD standard deviation.
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outcome measure in clinical trials11, 12. ERGs remain useful for providing an objective visual function prognosis in 
patients with RP. For example, it is estimated that less than 0.5 µV seen on a 30 Hz-flicker ERG can be considered 
‘virtual blindness’43. Voltages measured on 30 Hz-flicker can be used to estimate years left of useful vision, infor-
mation which is invaluable for patient counseling43.
In gene and cell-based therapy clinical trials, one eye typically serves as a control while the contralateral eye 
receives treatment, usually in the form of a subretinal injection. When assuming disease progression is symmetric 
between eyes, this provides investigators the unique opportunity to compare the treated eye to a near-ideal con-
trol. However, previous studies have estimated that 10–14.3% of patients have asymmetry when quantified with 
SD-OCT or SW-AF43, 45. Our previous two-year study estimated that 20% of patients have asymmetric progres-
sion8. Each study uses different statistical methods for measuring and defining asymmetry, which makes com-
paring cohorts difficult. We believe a more useful way of comparing both eyes may be with descriptive statistics. 
For this cohort, we observed that 95% of this cohort had less than a 154 µm per year difference in progression rate 
for EZ-line width. Horizontal and vertical ring diameters were less than a difference of 118 µm and 132 µm per 
year between eyes. Instead of defining asymmetry, investigators can use this data to cautiously assess the results 
of clinical trials and determine how large of a difference between the treated and control eye is necessary before 
considering a therapy to be efficacious in delaying structural progression.
Our study used mixed effect models to assess the effect of other variables on disease progression. For our 
cohort, we did not observe an effect of age or gender alone on disease progression rate, as anticipated. Progression 
rates did significantly differ when assessed as a function of initial structural measurement. For all structural 
measurements utilized for both eyes, except horizontal ring diameters, progression rates were significantly faster 
when initial baseline measurement was > 3000 μm. This is consistent with the fact that the natural history of RP 
progresses in an exponential decay43. Of note, progression did not vary significantly as a function of mode of 
inheritance. It is previously reported that XLRP has a faster rate of disease progression44. In our study, XLRP did 
not have a significantly faster disease progression rate. However, the small number (n = 4) for XLRP diminishes 
the confidence of this interpretation.
Some limitations to using SD-OCT and SW-AF as outcome measures include the presence of cystoid mac-
ular edema (CME), which blurs the EZ line, and the fact that patients do not always have an easily quantifiable 
hyperautofluorescent ring on SW-AF8. Of note, 13.6% of patients at initial visit in our cohort exhibited CME. No 
patient had a clinically significant staphyloma, although curvature of the posterior pole was not accounted for 
with the measurement utilized. This may cause an underestimation of changes in EZ-line width, as curvature of 
the posterior pole will distort measurements of the vertical component of changes in EZ line length. For patients 
in which the disease has not reached the last 30 degrees of the posterior pole, newer OCT techniques such as 
swept source will need to be employed as opposed to SD-OCT. In contrast, SW-AF imaging can image a wider 
field. This highlights the importance of a multi-modal assessment of RP patients. Other challenges include the 
genetic heterogeneity of RP, which is well-documented1, 6, 46, 47, and may make the interpretation of natural pro-
gression studies difficult. In our cohort, 35 patients (43%) harbored variants consistent with disease phenotype 
and family history, which is 8% more than the previous study. Certain mutations may manifest with a progression 
that is not similar to the average projection of large cohorts like ours, which encompass RP patients with differing 
molecular diagnoses. Additionally, many recessive RP cases are compound heterozygous, so patients may have a 
unique progression rate depending on the severity of each mutation. Only 6 patients (7%) in our study have yet 
to undergo either ffERG or genetic testing. However, each of these patients experienced symptoms and clinical 
progression strongly consistent with a rod-cone dystrophy. The authors recognize that some conditions may 
masquerade as RP prior to ffERG or genetic testing. Due to the genetic heterogeneity of RP, sub-group analyses 
of large cohorts or multi-center natural progression studies for a specific gene-associated disease are needed but 
challenging for rare diseases, and they may be more useful for gene therapy-based trials in which enrolled patients 
share a gene-specific RP diagnosis. Further studies with longer follow-up and correlation to functional measures 
of vision loss will continue to provide important analyses of disease progression in preparation for future clinical 
trials.
Methods
Subjects. The current investigation is a follow-up to Sujirakul et al.8 and contains overlapping patients. 
However, all raw data and analyses were newly acquired with an increased number of subjects, genotypes, images 
and longer follow-up period. All subjects provided informed consent to participate in this study, which was 
approved by the Columbia University Internal Review Board and adhered to the tenets of the Declaration of 
Helsinki. None of the data presented in this study, including images and genetic testing results, is identifiable to 
individual patients. RP patients followed at the Harkness Eye Institute electrodiagnostics clinic were considered 
for inclusion, of which 81 met our criteria: (1) the patient must be monitored for at least two visits, (2) the patient 
must have bilateral RP. Patients were excluded if image quality was poor or if the EZ line was not visible in con-
junction with an absence of a hyperautofluorescent ring. X-linked RP (XLRP) manifesting in females and para-
venous RP were excluded from our study. All cases of RP were diagnosed clinically by an inherited retinal disease 
specialist (S.H.T.) based on presenting symptoms, family history, and fundus exam and subsequently supported 
by imaging or ffERG. Sixty-eight patients (84%) underwent ffERG testing, which showed tracings consistent with 
a rod-cone dystrophy. Of the 13 patients who did not undergo electroretinography, seven harbored variants in 
genes that were consistent with their phenotype and family history.
Genetic analysis. Genetic testing was performed as described in our previous study8. Briefly, blood sam-
ples were drawn and sent to Oregon Health Sciences University. Extracted DNA was tested for published 
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genes that cause RP by parallel sequencing on Illumina HiSeq platform with 100 bp paired-end reads. Dideoxy 
chain-terminating sequencing was subsequently used to confirm the mutation.
Fundus autofluorescence and spectral-domain optical coherence tomography. All imaging was 
performed as described in our previous study8. Briefly, SW-AF images were acquired at each visit on dilated 
patients using the Spectralis HRA + OCT device (Heidelberg Engineering, Heidelberg, Germany) at a resolution 
of 1536 × 1536 pixels and a field of view of 30 degrees. For large hyperfluorescent rings, a 55-degree field of view 
was acquired. A 521 nm barrier filter was used to filter emitted light after excitation with a wavelength of 486 nm. 
The external boundary of the ring, which is more distinct than the internal boundary, was measured manually 
using the inbuilt software (Heidelberg Eye Explorer, software version 1.9.10.0, Heidelberg, Germany). One axis, 
vertical or horizontal, was measured if the patient had a hyperautofluorescent arc or a ring that fell outside of 
the optic nerve, making one diameter unmeasurable. At each visit, SD-OCT images were acquired using the 
Spectralis HRA + OCT device (Heidelberg Engineering, Heidelberg, Germany) with an 870 nm light source and 
automatic real-time registration program of both an SD-OCT and infrared reflectance (IR-R) image. Horizontal 
scans taken through the fovea provided visualization of the EZ-line and was measured manually using spectralis 
software. All SD-OCT images were acquired in high resolution mode (9 mm scans, ART, average of a minimum 
of 50 images).
Statistical analyses. Measurements were obtained from SD-OCT and fundus SW-AF images recorded for 
all visits of each patient in the cohort. EZ-line width and horizontal and vertical hyperfluorescent ring diameters 
were measured twice by the first author (T.C.) one week apart (Fig. 1). Progression rates and test-retest reliability 
of measurements were calculated as previously described8. Reliability was assessed with descriptive statistics for 
differences between test-retest values and by calculating intraclass correlation coefficients of test-retest meas-
urements. Pearson correlations were used to compare structural measurements for the initial visit. Progression 
rates were estimated using linear mixed models with random intercepts and slopes, where the random slope for 
a subject was his/her estimated change over time. Left and right eyes were compared by calculating the absolute 
difference between the random slopes and using descriptive statistics to quantify the asymmetry within various 
percentiles. Linear mixed models were fit for other factors of interest such as: age, gender, mode of inheritance, 
and initial baseline measurement. Initial baseline measurement was assessed as a dichotomized (Table SV) and 
continuous (Table SVI) variable. The models which were fit included time, the factors of interest, and the interac-
tion of this factor with time. Statistical analyses were done using R version 3.3.1, and also utilizing utilized nlme 
and lme4 sub packages (Vienna, Austria).
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